Induction Immunosuppression in a Sensitized Second Transplant
A repeat transplant candidate with a measurable donor-specific antibody and a negative crossmatch sits between two induction agents built for two different pictures of risk — and the honest answer may depend less on which drug is chosen than on when the antibody was last checked.
Renata S. is thirty-four and due back in her middle-school science classroom this fall, a return she has already had to explain twice to her seventh graders, both times because a kidney her mother gave her nine years ago was, in its own quiet way, running out of time. It failed fourteen months ago to biopsy-proven chronic active antibody-mediated rejection, not to anything she did wrong — she took every dose, kept every appointment — and she has been on hemodialysis through a left forearm fistula since. A deceased-donor kidney has now been offered.
The offer comes with a harder immunologic picture than her first transplant did. Her calculated panel-reactive antibody is 62%, built almost entirely from antibodies her body raised against her mother's own mismatched HLA antigens during that first graft's decline — exposure a first-time transplant candidate never carries. Solid-phase testing against this new donor finds one donor-specific antibody at a low-to-moderate MFI, and the flow crossmatch performed the same day reads negative: real antibody, but not at a level or a configuration that has crossed into a positive functional crossmatch. She has never lost a graft to hyperacute rejection and has no other chronic illness — her own record, aside from a DEXA scan showing early osteopenia from nine years of prior steroid exposure, is otherwise clean. The question in front of the team is whether that one antibody, sitting below the crossmatch threshold today, is stable or still climbing, and how much that answer should be allowed to change before the operating room.
Two trials, not one, are why her second-transplant status is doing real work here, not just her antibody number. INTAC supplies the risk definition — repeat transplant, or a PRA of 20% or more — and Renata meets both independently, which is a different claim than meeting either alone. What INTAC never did is compare her two candidate drugs: basiliximab appeared only in its low-risk arm. The head-to-head she needs is Brennan's Thymoglobulin Induction Study, where rATG beat basiliximab on acute rejection in deceased-donor recipients — her own donor type — at high risk. What neither trial tells the team is how a negative crossmatch carrying one low-titer antibody behaves inside that category. Her transplant team has ordered a repeat solid-phase antibody panel for the morning of surgery specifically because a single titer drawn in clinic ten days ago cannot, by itself, distinguish an antibody that has already plateaued from one still climbing toward the crossmatch threshold it hasn't yet crossed.
Pre-operative huddle, induction-agent selection
I want rabbit antithymocyte globulin, not basiliximab, and I want it because of where she already sits, not because of what might happen. Brennan's Thymoglobulin Induction Study randomized a five-day rATG course head-to-head against basiliximab in deceased-donor recipients at high risk for rejection or delayed graft function, and rATG came out ahead on both the incidence and the severity of acute rejection. I want to be precise about what INTAC does and doesn't add here: it defines the high-risk category — repeat transplant, PRA of 20% or more — but it never randomized rATG against basiliximab, so it can't be the trial that picks between them. Renata meets two of INTAC's three high-risk criteria at once, and she is exactly Brennan's donor type.
If this were her first transplant with the same low-titer DSA and no sensitizing history behind it, I would be arguing the other direction. The repeat-transplant status is doing real work here, not just the number.
I'd push back on treating either trial as though it settles this case specifically. Brennan's patients were selected largely on delayed-graft-function risk — long cold ischemia, marginal donors — and a letter in the same journal made precisely that objection at the time: the enrolled cohort wasn't demonstrably high immunologic risk in the classical sense of a high PRA or a prior graft lost to rejection. INTAC's stratum is a category definition, not a demonstration that rATG beats basiliximab inside it. Her crossmatch is negative, her MFI is low-to-moderate, single specificity. Depletion isn't a free upgrade; it buys a real, dose-dependent increase in early viral and fungal infection, and a lifetime PTLD risk that compounds with every future induction she may need if this graft, too, doesn't last her whole life.
The risk-category argument isn't wrong on its own terms — I'm not disputing that repeat transplant plus elevated cPRA describes higher-risk patients as a category. What I'm disputing is carrying a result obtained in one high-risk population across to her as though the label alone made the two the same patient, when her actual antibody profile sits well inside the range where basiliximab has not shown a measurable rejection penalty.
Both of you are arguing from a single number drawn ten days ago, and that's the piece I'd change before either drug gets picked. A DSA this early after its first appearance is a trajectory, not a fixed fact — some of these antibodies climb steadily toward a positive crossmatch, and some plateau and never get there. What she needs before this decision is final is a repeat solid-phase panel drawn as close to the operating room as the lab can turn around.
If the titer has held flat or fallen, I'd side with basiliximab on the reasoning already laid out — the measured risk simply isn't there. If it has risen meaningfully, even short of a positive crossmatch, I'd give rATG at a reduced cumulative dose rather than the standard six-milligram total — enough T-cell depletion to answer the rising antibody without paying the full infection and malignancy cost of a full course built for a crossmatch-positive patient she may not actually be.
The repeat solid-phase panel, drawn the morning of transplant, showed her single DSA had risen from its outpatient MFI — not into positive-crossmatch range, but enough of a trend that the immunologist's proposed reduced-dose rATG course was accepted by both other voices as the correct resolution, closer to the physician's original position than the pharmacist's, but at a dose neither had originally proposed.
Not agreed, and carried forward rather than resolved: how the same trajectory-based reasoning should apply the next time her antibody panel is checked, at three months post-transplant. The pharmacist wants a pre-specified MFI threshold, set now, above which a change in maintenance immunosuppression is automatically triggered rather than re-litigated case by case; the physician would rather read each future panel on its own terms, given how much the induction-day decision itself turned on a single sample drawn at the right moment rather than a rule set in advance.